ACE-031 Peptide – User Manual & Research Protocol Guide

ACE-031 is a recombinant fusion protein studied for its ability to bind and inhibit myostatin and related ligands involved in muscle growth regulation. In research environments, it is explored for anabolic signaling pathways, muscle mass regulation, and body composition physiology models.

Research Applications

Myostatin pathway inhibition studies
Muscle growth and hypertrophy research models
Anabolic signaling investigations
Body composition and performance physiology studies
Ligand-binding and receptor interaction research

Disclaimer: ACE-031 is for research and experimental use only and is not FDA-approved for therapeutic use.

Lyophilized Powder

Freeze-dried ACE-031 intended for reconstitution prior to use in research settings.

Reconstituted Solution

Prepared liquid form used as an injectable research preparation after proper reconstitution.

ACE-031 is studied for its ability to:

• Bind and neutralize myostatin signaling pathways
• Inhibit activin receptor ligands involved in muscle regulation
• Promote muscle growth signaling in experimental models
• Support anabolic and regenerative pathway research
• Influence body composition physiology mechanisms

Observed effects are derived from preclinical and investigational research settings.

Subcutaneous (SC) – Standard Research Model

Typical research protocols use 1–3 mg per administration, generally once weekly, often in myostatin inhibition research models.

Short-Course Research

Some studies use 1–2 mg weekly in limited-duration research protocols.

Protocol-Based Study

Dosing and frequency may be protocol-dependent, determined by the specific research design and objectives.

Important

There is no approved human dosage. The ranges above reflect commonly cited research patterns only.

Initiation

A 1–2 week phase used for initial response observation at the start of the study.

Active Study Phase

Typically 4–8 weeks, focused on evaluating myostatin pathway activity.

Rest Period

A 4+ week interval between research cycles to allow recovery and system reset.

Note

Cycle duration may vary depending on the study design and research endpoints.

Supplies

Sterile bacteriostatic water
Sterile syringe
Alcohol swabs

General Procedure

1. Clean vial stopper with alcohol.
2. Add bacteriostatic water to desired concentration.
   Example: 3 mg vial + 1 mL → 3 mg/mL
3. Swirl gently to dissolve (do not shake).
4. Refrigerate at 2–8°C after reconstitution.
5. Use within 2–4 weeks or per protocol.

Maintain sterile technique
Rotate administration sites in injectable models
Document preparation concentration and date
Follow institutional research standards

Lyophilized Powder

Store in a cool, dry environment to maintain stability, with a shelf life of up to 12 months.

Reconstituted Solution

Keep refrigerated at 2–8°C and use within 2–4 weeks after preparation.

Protection Guidelines

Protect from light, heat, and contamination to preserve product quality.

Safety Note

Discard the solution if it becomes cloudy or discolored, as this may indicate contamination or degradation.

Research use only
Not for therapeutic application
Human safety outside controlled research is not established
Potential research observations: injection-site irritation
Maintain sterile handling technique
Keep out of reach of unauthorized personnel

Peptide: ACE-031
Category: Performance & Muscle Growth Research
Delivery: Injectable research model
Typical Investigational Range: 1–3 mg per administration
Cycle: 4–8 week research protocols
Storage: Refrigerated after reconstitution